Cytori Therapeutics, Inc. Selected by Fraunhofer Institute for Cell Therapy and Immunology (IZI) to Develop New Stem and Regenerative Cell-Based Treatments for Stroke

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) formed collaboration to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The Fraunhofer Society will commit $425,000 over two years in support to Cytori’s already planned research and development.

MORE ON THIS TOPIC